In vitro cytokine secretion in individuals with schizophrenia: Results, confounding factors, and implications for further research

Brain, Behavior, and Immunity

Volumn 15, Issue 4, 2001, Pages 282-318

  Hinze Selch, Dunja ^a   Pollmächer, Thomas ^b  

^a UNIVERSITY OF KIEL   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Antipsychotic drugs; Cytokines; In vitro; Medication; Peripheral blood cells; Schizophrenia; Secretion; Smoking

Indexed keywords

ALPHA INTERFERON; CLOZAPINE; CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; HALOPERIDOL; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; NEUROLEPTIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

BIOASSAY; CIGARETTE SMOKING; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE COURSE; IMMUNE SYSTEM; LEUKOCYTE; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; STATISTICAL ANALYSIS;

EID: 0035675872     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1006/brbi.2001.0645     Document Type: Article

References (162)

1. Mouse tumor necrosis factor-alpha increases brain tryptophan concentrations and norepinephrine metabolism while activating the HPA axis in mice
2. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment
3. Production of interferon-gamma in families with multiple occurrence of schizophrenia
4. Cytokine expression and molecular mechanisms of their auto/paracrine regulation of anterior pituitary function and growth
5. Pathophysiological role of the cytokine network in the anterior pituitary gland
6. Monoclonal cytolytic T-cell lines
7. RANTES promotes growth and survival of human first-trimester forebrain astrocytes
8. Cytokines in neuronal cell types
9. The cytokine network of wallerian degeneration: IL-10 and GM-CSF
10. Cytokine actions in the central nervous system
11. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients
12. A specific and reliable bioassay for the detection of femtomolar levels of human and murine tumor necrosis factors
13. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha
14. Transgenic models to assess the pathogenic actions of cytokines in the central nervous system
15. Increased plasma interleukin-1 activity in women after ovulation
16. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour
17. Cytokine profiles in drug-naive schizophrenic patients
18. Cytokine-induced sickness behavior: Where do we stand?
19. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia
20. Cloning and structure of the human interleukin 2 chromosomal gene
21. Inflammatory cytokines and related genes are induced in the rat hippocampus by limbic status epilepticus
22. Haemophilus influenzae and Streptococcus pneumoniae induce different intracerebral mRNA cytokine patterns during the course of experimental bacterial meningitis
23. ELISA kits based on monoclonal antibodies do not measure total 1L-1β synthesis
24. Schizophrenic psychosis: A contraindication for treatment of hepatitis C with interferon alpha?
25. Urinary excretion of biopterin and neopterin in psychiatric disorders
26. Cytokine activation of the HPA axis
27. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress
28. The sympathetic nerve - An integrative interface between two supersystems: The brain and the immune system
29. In situ hybridization histochemistry localization of interleukin-3 mRNA in mouse brain
30. Soluble cytokine receptors: Basic immunology and clinical applications
31. Interleukin 3: From colony-stimulating factor to pluripotent immunoregulatory cytokine
32. Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients
33. Altered interleukin 2 production in schizophrenia: Association between clinical state and autoantibody production
34. Decreased interleukin-2 production in schizophrenic patients
35. Rat microglial interleukin-3
36. Cytokines, receptors, and inhibitors
37. The effect of irradiation on the release of lymphocyte-activating factor (LAF)
38. Exposure to infection and brain development: Cytokines in the pathogenesis of schizophrenia
39. Interleukin-1 of the central nervous system is produced by ameboid microglia
40. Differential effects of BDNF, ADNF9, and TNF-alpha on levels of NMDA receptor subunits, calcium homeostasis, and neuronal vulnerability to excitotoxicity
41. Involvement of the LPS receptor in the induction of interleukin-1 in human monocytes stimulated with endotoxins
42. T lymphocyte-macrophage interactions in cellular antibacterial immunity
43. Neurotoxic consequences of central long-term administration of interleukin-2 in rats
44. Interleukin-2 as a neuroregulatory cytokine
45. Phasic hyperactivity of the HPA axis resulting from chronic central IL-2 administration
46. Sensitization to the effects of tumor necrosis factor-alpha: Neuroendocrine, central monoamine, and behavioral variations
47. Effects of clozapine on in vitro immune parameters: A longitudinal study in clozapine-treated schizophrenic patients
48. Human peripheral blood lymphocytes. Isolation, subset characterization and in vitro properties. A review of the literature of the 1970s
49. Production of interferons and lymphokines in leukocyte cultures of patients with schizophrenia
50. An IL-1 receptor and an IL-1 receptor antagonist attenuate muramyl dipeptide- and IL-1-induced sleep and fever
51. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro
52. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain
53. Roles of cytokines in the neural-immune interactions: Modulation of NMDA responses by IFN-alpha
54. Production of interferon-α and -γ by leukocytes from patients with schizophrenia
55. Decreased interleukin-2 production in Korean Schizophrenic patients
56. A whole-blood technique for testing the production by leukocytes of human interferon
57. C-fos and IL-2 gene expression in rat brain cells and splenic lymphocytes after non-antigenic and antigenic stimuli
58. Cytokines and the brain: Implications for clinical psychiatry
59. Humoral regulation of physiological sleep: Cytokines and GHRH
60. Interleukin-10 inhibits spontaneous sleep in rabbits
61. The influence of a targeted deletion of the IFN-gamma gene on emotional behaviors
62. Purification of human interleukin I
63. Central monoamine activity following acute and repeated systemic interleukin-2 administration
64. Expression of tumor necrosis factor alpha (TNF alpha) and interleukin 6 (IL-6) mRNA in adult human astrocytes: Comparison with adult microglia and fetal astrocytes
65. An improved assay for the detection of interleukin I
66. Behavioral effects of cytokines
67. Assay of interferon and viral antibodies in the cerebrospinal fluid in clinical neurology and psychiatry
68. Psychopharmaca and electro-convulsive therapy in relation to viral antibodies and interferon. Experimental and clinical study
69. Plasma-soluble intefieukin-2 and transferrin receptor in schizophrenia and major depression
70. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects
71. Endocrine, paracrine and autocrine actions of prolactin on immune cells
72. Cytokine regulation of neuronal differentiation of hippocampal progenitor cells
73. Effect of clozapine on human serum prolactin levels
74. Tumor necrosis factor alpha, interleukin-1 and related cytokines in brain development: Normal and pathological
75. Lipopolysaccharide-induced changes in monoamines in specific areas of the brain: Blockade by interleukin-1 receptor antagonist
76. Decreased production of interferon alpha and interferon gamma in leukocyte cultures of schizophrenic patients
77. Human first trimester forebrain cells express genes for inflammatory and anti-inflammatory cytokines
78. Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders
79. Dose-dependent effects of endotoxin on human sleep
80. Hypophysectomy enhances interleukin-1 beta, tumor necrosis factor-alpha, and interleukin-10 mRNA expression in the rat brain
81. The interferon system of patients with schizophrenia during therapy
82. Antidepressant drug-induced alterations in neuron-localized tumor necrosis factor-alpha mRNA and alpha(2)-adrenergic receptor sensitivity
83. Increased production of interleukin-2 (IL-2) but not soluble interleukin-2 receptors (sIL-2R) in unmedicated patients with schizophrenia and schizophreniform disorder
84. Cigarette smoking decreases interleukin-8 secretion by human alveolar macrophages
85. Somnogenic and pyrogenic effects of interleukin-1beta and lipopolysaccharide in intact and vagotomized rats
86. Suppression of human IL-1beta, IL-2, IFN-gamma, and TNF-alpha production by cigarette smoke extracts
87. Tumour necrosis factor-alpha and interleukin-2 differentially affect hippocampal serotonergic neurotransmission, behavioural activity, body temperature and hypothalamic-pituitary-adrenocortical axis activity in the rat
88. Production of tumor necrosis factor alpha by rat alveolar macrophages collected after acute cigarette smoking
89. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2
90. Cytokine-induced anorexia. Behavioral, cellular, and molecular mechanisms
91. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome
92. Factors confounding studies of circulating soluble interleukin-2 receptor levels in schizophrenia
93. Effects of clozapine on plasma cytokine and soluble cytokine receptor levels
94. Smoking affects plasma soluble interleukin-2 receptor levels in patients with schizophrenia
95. Experimental immunomodulation, sleep and sleepiness in humans
96. Chronic interleukin-6 alters NMDA receptor-mediated membrane responses and enhances neurotoxicity in developing CNS neurons
97. IL-2 induces vasopressin release from the hypothalamus and the amygdala: Role of nitric oxide-mediated signaling
98. Interferon-alpha and transforming growth factor-beta 1 regulate corticotropin-releasing factor release from the amygdala: Comparison with the hypothalamic response
99. Cytokine-associated emotional and cognitive disturbances in humans
100. Mechanisms of altered prolactin secretion due to the administration of interleukin-1 beta into the brain ventricles of the rat
101. Human T-cell growth factor: Purification and interaction with a cellular receptor
102. Mediators of immunity: Lymphokines and monokines
103. Review of immunological and immunopathological findings in schizophrenia
104. Cytokine production in unmedicated and treated schizophrenic patients
105. Production of cytokines in acute schizophrenic psychosis
106. Immunological dysfunction in schizophrenia: A systematic approach
107. Cytokines and the nervous system II: Actions and mechanisms of action
108. Interleukin 1 in the brain: Biology, pathology and therapeutic target
109. Purification and biochemical characterization of human lymphocyte mitogenic factor (LMF)
110. Comparative effect of IL-2 and IL-6 on morphology of cultured hippocampal neurons from fetal rat brain
111. Cytokine network in the central nervous system and its roles in growth and differentiation of glial and neuronal cells
112. No evidence for autoimmunity in schizophrenia
113. Role of interleukin-6 in the neuroendocrine system
114. Gene expression and function of interleukin-1, interleukin-6 and tumor necrosis factor in the brain
115. Plasma levels of cytokines and soluble cytokine receptors during treatment with olanzapine
116. T-helper-1 and T-helper-2 responses in psychiatric disorders
117. In vitro production of IL-6, IL-1 beta, and tumor necrosis factor-alpha by human embryonic microglial and neural cells
118. Cytokines in the central nervous system: Regulatory roles in neuronal function, cell death and repair
119. Disorders of interleukin 2 biosynthesis by peripheral blood lymphocytes in patients with schizophrenia
120. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain
121. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients
122. IL-10 as a mediator in the HPA axis and brain
123. Cigarette smoking decreases bioactive interleukin-6 secretion by alveolar macrophages
124. Emotions, stress, the central nervous system, and immunity
125. Differential involvement of central and peripheral norepinephrine in the central lipopolysaccharide-induced interleukin-6 responses in mice
126. Immunosuppressive effects of clozapine and haloperidol: Enhanced production of the interleukin-1 receptor antagonist
127. Variations of nucleus accumbens dopamine and serotonin following systemic interleukin-1, interleukin-2 or interleukin-6 treatment
128. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men
129. Interferon-alpha acutely impairs sleep in healthy humans
130. Comparative evaluation of cytokine profiles and reactive gliosis supports a critical role for interleukin-6 in neuron-glia signaling during regeneration
131. Astrocytes produce interferon that enhances the expression of H-2 antigens on a subpopulation of brain cells
132. Cytokine and microbially induced sleep responses of interleukin-10 deficient mice
133. Interferon-gamma and Ia antigen are present on astrocytes in active chronic multiple sclerosis lesions
134. Brain-periphery connections: Do they play a role in mediating the effect of centrally injected interleukin-1 beta on gonadal function?
135. The schizophrenia-rheumatoid arthritis connection: Infectious, immune, or both?
136. Herpes simplex infection of HEp-2 and L-929 cells. 2. The kinetics of virus multiplication and cell lysis, and the measurement of interferon production
137. Interferon induced in human leukocytes by concanavalin A: Isolation and characterization of gamma- and beta-type components
138. Evidence that folliculo-stellate cells mediate the inhibitory effect of interferon-gamma on hormone secretion in rat anterior pituitary cell cultures
139. Involvement of nitric oxide in the interferon-gamma-induced inhibition of growth hormone and prolactin secretion in anterior pituitary cell cultures
140. Interleukin-6 expression and regulation in astrocytes
141. A new concept in neurodegeneration: TNF-alpha is a silencer of survival signals
142. Aberrant T-cell mediated immunity in untreated schizophrenic patients: Deficient interleukin-2 production
143. Decreased production of interleukin-2 in schizophrenia
144. Modulation of the promoter region of prepro-hypocretin by alpha-interferon
145. The psychological and psychiatric effects of rIL-2 therapy: A controlled clinical trial
146. Interleukin-3 and interleukin-6 stimulate cortisol secretion from adult human adrenocortical cells
147. Interleukin 3 prevents delayed neuronal death in the hippocampal CA1 field
148. Induction of pituitary cytokine transcripts by peripheral lipopolysaccharide
149. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients
150. Interleukin (1L) 1 beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications
151. An in situ hybridization study on interleukin-1 beta mRNA induced by transient forebrain ischemia in the rat brain
152. The interferon family stimulates the secretions of prolactin and interleukin-6 by the pituitary gland in vitro
153. Effect of TNF-alpha on prolactin secretion from rat anterior pituitary and dopamine release from the hypothalamus: Comparison with the effect of interleukin-1 beta
154. Interleukin-1alpha injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and increases release of dopamine and serotonin
155. An association between anti-hippocampal antibody concentration and lymphocyte production of IL-2 in patients with schizophrenia
156. Interleukin-3: Molecular biology and biologic activities
157. Interleukin-2 modulates N-methyl-D-aspartate receptors of native mesolimbic neurons
158. Viruses, schizophrenia, and bipolar disorder
159. Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity
160. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6
161. Delineation of the proinflammatory cytokine cascade in fever induction